Cargando…

Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test

PURPOSE: To assess changes in the central and peripheral contrast sensitivity in severe primary open-angle glaucoma (POAG) patients using a computer-based Spaeth/Richman contrast sensitivity test (SPARCS) over a period of 24 months. METHODS: Our pilot, observational study included 15 patients (30 ey...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichhpujani, Parul, Singh, Tanu, Thakur, Sahil, Singh, Rohan Bir, Kumar, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780179/
https://www.ncbi.nlm.nih.gov/pubmed/33447729
http://dx.doi.org/10.1177/2515841420977412
_version_ 1783631463109885952
author Ichhpujani, Parul
Singh, Tanu
Thakur, Sahil
Singh, Rohan Bir
Kumar, Suresh
author_facet Ichhpujani, Parul
Singh, Tanu
Thakur, Sahil
Singh, Rohan Bir
Kumar, Suresh
author_sort Ichhpujani, Parul
collection PubMed
description PURPOSE: To assess changes in the central and peripheral contrast sensitivity in severe primary open-angle glaucoma (POAG) patients using a computer-based Spaeth/Richman contrast sensitivity test (SPARCS) over a period of 24 months. METHODS: Our pilot, observational study included 15 patients (30 eyes) with severe POAG. Visual acuity, intraocular pressure, number of anti-glaucoma drugs, visual fields, and SPARCS score were recorded at first visit and at 12 and 24 months. RESULTS: We observed changes in mean deviation (MD) from −19.37 ± 5.04 to −20.63 ± 4.07, mean pattern standard deviation (PSD) from 11.49 ± 2.61 to 11.35 ± 2.01, and mean SPARCS score from 54.97 ± 15.66 to 53.50 ± 16.42. We found no statistically significant difference between visual field parameters and SPARCS scores associated with the number or type of prescribed anti-glaucoma drugs. Spearman’s correlation coefficient of SPARCS at baseline (SPARCS1) versus MD at baseline (MD1) was 0.274 (p = 0.142) and SPARCS1 versus PSD at baseline (PSD1) was −0.163 (p = 0.389). The correlation coefficient between SPARCS at 12 months (SPARCS2) versus MD (MD2) at the same time point was computed to be 0.391 (p = 0.03), whereas SPARCS2 versus PSD at 12 months was −0.212 (p = 0.262). Similarly, we found the coefficient to be 0.336 (p = 0.069) for SPARCS3 (SPARCS at 24 months) versus MD3 (MD at 24 months) and −0.242 (p = 0.197) for SPARCS3 versus PSD3 (PSD at 24 months). Correlation coefficients between SPARCS1/2, SPARCS1/3, MD1/2, MD1/3 PSD1/2, and PSD1/3 were 0.856, 0.865, 0.748, 0.722, 0.497, and 0.562, respectively (p < 0.001). MD changed by 9.46% ± 12.73%, PSD by 0.64% ± 14.03%, and average SPARCS by 3.31% ± 12.73% over 24 months. CONCLUSION: The data from our study indicate the utilitarian application of SPARCS, an inexpensive and readily available tool for monitoring functional deterioration in cases with advanced glaucomatous damage, especially in resource-poor settings. Furthermore, it is a useful and reliable alternative to the imaging modalities where retinal nerve fiber layer measurement can be erroneous in advanced cases secondary to the floor effect.
format Online
Article
Text
id pubmed-7780179
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77801792021-01-13 Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test Ichhpujani, Parul Singh, Tanu Thakur, Sahil Singh, Rohan Bir Kumar, Suresh Ther Adv Ophthalmol Original Research PURPOSE: To assess changes in the central and peripheral contrast sensitivity in severe primary open-angle glaucoma (POAG) patients using a computer-based Spaeth/Richman contrast sensitivity test (SPARCS) over a period of 24 months. METHODS: Our pilot, observational study included 15 patients (30 eyes) with severe POAG. Visual acuity, intraocular pressure, number of anti-glaucoma drugs, visual fields, and SPARCS score were recorded at first visit and at 12 and 24 months. RESULTS: We observed changes in mean deviation (MD) from −19.37 ± 5.04 to −20.63 ± 4.07, mean pattern standard deviation (PSD) from 11.49 ± 2.61 to 11.35 ± 2.01, and mean SPARCS score from 54.97 ± 15.66 to 53.50 ± 16.42. We found no statistically significant difference between visual field parameters and SPARCS scores associated with the number or type of prescribed anti-glaucoma drugs. Spearman’s correlation coefficient of SPARCS at baseline (SPARCS1) versus MD at baseline (MD1) was 0.274 (p = 0.142) and SPARCS1 versus PSD at baseline (PSD1) was −0.163 (p = 0.389). The correlation coefficient between SPARCS at 12 months (SPARCS2) versus MD (MD2) at the same time point was computed to be 0.391 (p = 0.03), whereas SPARCS2 versus PSD at 12 months was −0.212 (p = 0.262). Similarly, we found the coefficient to be 0.336 (p = 0.069) for SPARCS3 (SPARCS at 24 months) versus MD3 (MD at 24 months) and −0.242 (p = 0.197) for SPARCS3 versus PSD3 (PSD at 24 months). Correlation coefficients between SPARCS1/2, SPARCS1/3, MD1/2, MD1/3 PSD1/2, and PSD1/3 were 0.856, 0.865, 0.748, 0.722, 0.497, and 0.562, respectively (p < 0.001). MD changed by 9.46% ± 12.73%, PSD by 0.64% ± 14.03%, and average SPARCS by 3.31% ± 12.73% over 24 months. CONCLUSION: The data from our study indicate the utilitarian application of SPARCS, an inexpensive and readily available tool for monitoring functional deterioration in cases with advanced glaucomatous damage, especially in resource-poor settings. Furthermore, it is a useful and reliable alternative to the imaging modalities where retinal nerve fiber layer measurement can be erroneous in advanced cases secondary to the floor effect. SAGE Publications 2020-12-28 /pmc/articles/PMC7780179/ /pubmed/33447729 http://dx.doi.org/10.1177/2515841420977412 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Ichhpujani, Parul
Singh, Tanu
Thakur, Sahil
Singh, Rohan Bir
Kumar, Suresh
Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test
title Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test
title_full Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test
title_fullStr Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test
title_full_unstemmed Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test
title_short Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test
title_sort assessing glaucoma deterioration using spaeth/richman contrast sensitivity test
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780179/
https://www.ncbi.nlm.nih.gov/pubmed/33447729
http://dx.doi.org/10.1177/2515841420977412
work_keys_str_mv AT ichhpujaniparul assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest
AT singhtanu assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest
AT thakursahil assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest
AT singhrohanbir assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest
AT kumarsuresh assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest